VentureBeat

TODAY’S HEADLINES:

• AcryMed, wound-healing specialist, sells itself to I-Flow for $25M (release)
• Stent maker Devax pulls $85M IPO filing (Edgar)
• Cempra Pharma gets $10M for anti-infective drugs (TechJournal South)
• Genesis Genomics takes in C$312K for DNA-based diagnostics (GenomeWeb)

AcryMed, wound-healing specialist, sells itself to I-Flow for $25M — AcryMed, a Beaverton, Ore., device maker focused on bleeding control and wound healing, agreed to sell itself to I-Flow, a publicly traded maker of drug-delivery systems, for $25 million in cash. The release is here.

AcryMed currently markets several types of wound dressings that use ionic silver — which apparently has antimicrobial properties — to prevent infection and “microlattices” to promote healing. AcryMed has also developed a technique for depositing silver particles on the surface of medical devices to prevent bacterial contamination. I-Flow says it expects the company’s technology to assist in developing new antimicrobial catheters and silver-based transparent wound dressings.

Cempra Pharma gets $10M for anti-infective drugs — Cempra Pharmaceuticals, a Research Triangle Park, N.C., specialty pharma focused on new drugs for overcoming antibiotic resistance, raised $10 million in a second funding round. Investors included Aisling Capital, Intersouth Partners, Optimer Pharmaceuticals and banker I. Wistar Morris.

That round is apparently still open, as PE Hub sourced its report to a regulatory filing. Cempra appears to have licensed its antibiotic candidates and its technology platform from Optimer Pharmaceuticals, with whom it concluded a deal in April 2006.